IP Library Granted Patent US 11,047,007
Granted Patent B1
US 11,047,007 · App. 16/912,446 · Granted Jun 29, 2021

Polynucleotides for amplification and detection of SARS-CoV-2

Inventors: Nadya Andini (Livermore, CA); Kathy Chiu (Irvine, CA); Xuewen Jiang (Cupertino, CA); Hédia Maamar (El Dorado Hills, CA)
Assignee: Talis Biomedical Corporation
C12Q1/6876C12Q1/6813C12Q1/6844C12Q2521/101C12Q2521/107C12Q2531/119
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,047,007
App. No.
16/912,446
Granted
Jun 29, 2021
Kind
B1
Abstract

Disclosed herein are primers and probes related to the detection of SARS-CoV-2 via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of SARS-CoV-2 in test samples and/or to diagnose Covid-19. Specifically, the present disclosure describes primers and probes that bind to the N gene, ORF1ab, or E gene of SARS-CoV-2 coronavirus for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

Claims (9)

1. A composition comprising SEQ ID NO.: 63, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 66, SEQ ID NO.: 67, and SEQ ID NO.: 68.

2. The composition of claim 1 , further comprising a molecular beacon comprising a fluorophore, a quencher and SEQ ID NO. 77.

3. The composition of claim 2 , further comprising SEQ ID NO.: 49, SEQ ID NO.: 50, SEQ ID NO.: 51, SEQ ID NO.: 52, SEQ ID NO.: 53, and SEQ ID NO.: 54.

4. The composition of claim 3 , further comprising a molecular beacon comprising a fluorophore, a quencher, and SEQ ID NO. 83.

5. The composition of claim 1 , further comprising an intercalating dye.

6. The composition of claim 1 , further comprising SEQ ID NO.: 49, SEQ ID NO.: 50, SEQ ID NO.: 51, SEQ ID NO.: 52, SEQ ID NO.: 53, and SEQ ID NO.: 54.

7. The composition of claim 6 , further comprising a molecular beacon comprising a fluorophore, a quencher, and SEQ ID NO. 83.

8. The composition of claim 6 , further comprising a strand displacement polymerase and reverse transcriptase.

9. The composition of claim 1 , further comprising a strand displacement DNA polymerase and a reverse transcriptase.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE STATE/COUNTRY ON THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 66986 FRAME: 149. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 11, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 067097/0916 →
CHANGE OF ADDRESS FROM 3400 BRIDGE PARKWAY, REDWOOD CITY TO 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0144 →
CHANGE OF ADDRESS FROM 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY TO 1375 WEST FULTON MARKET, SUITE 700, CHICAGO. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0149 →
CHANGE OF ADDRESS FROM 230 CONSTITUTION DRIVE, MENLO PARK TO 3400 BRIDGE PARKWAY, REDWOOD CITY. Recorded Mar 27, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066926/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2020
From: ANDINI, NADYA; CHIU, KATHY; JIANG, XUEWEN; MAAMAR, HÉDIA
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 053074/0261 →
Continuity (2)
Provisional Application 63009803 · Apr 14, 2020
Provisional Application 62993523 · Mar 23, 2020
Cited By (2)
US 12,264,365 US 12,275,999